Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Deucrictibant

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Pharvaris Reports 2025 Financial Results And Business Update
    Pharvaris Reports 2025 Financial Results And Business Update

    02 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/02/3267207/0/en/Pharvaris-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Update.html

    GLOBENEWSWIRE
    02 Apr 2026
    Share Share
    Lancet Haematology Publishes Deucrictibant Efficacy, Safety Data
    Lancet Haematology Publishes Deucrictibant Efficacy, Safety Data

    20 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/20/3259646/0/en/Evidence-of-Efficacy-and-Safety-of-Deucrictibant-for-Prophylaxis-and-On-Demand-Treatment-of-Hereditary-Angioedema-Attacks-Published-Back-to-Back-in-The-Lancet-Haematology.html

    GLOBENEWSWIRE
    20 Mar 2026
    Share Share
    Deucrictibant Shows Promise in Bradykinin Angioedema Treatment
    Deucrictibant Shows Promise in Bradykinin Angioedema Treatment

    02 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/02/3247196/0/en/Deucrictibant-Data-Supporting-Potentially-Differentiated-Profile-for-the-On-Demand-and-Prophylactic-Treatment-of-Bradykinin-Mediated-Angioedema-Presented-at-AAAAI-2026.html

    GLOBENEWSWIRE
    02 Mar 2026
    Share Share
    Pharvaris Outlines 2026 Strategic Priorities
    Pharvaris Outlines 2026 Strategic Priorities

    12 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/12/3216675/0/en/Pharvaris-Outlines-2026-Strategic-Priorities.html

    GLOBENEWSWIRE
    12 Jan 2026
    Share Share
    Pharvaris Reports Deucrictibant's Efficacy In HAE Attack
    Pharvaris Reports Deucrictibant's Efficacy In HAE Attack

    03 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/03/3198720/0/en/Pharvaris-Announces-Positive-Topline-Data-from-RAPIDe-3-Pivotal-Study-Confirming-Potential-of-Deucrictibant-for-On-Demand-Treatment-of-HAE-Attacks.html

    GLOBENEWSWIRE
    03 Dec 2025
    Share Share
    Pharvaris to Present Deucrictibant Data at 2025 US HAEA Summit
    Pharvaris to Present Deucrictibant Data at 2025 US HAEA Summit

    27 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/27/3106463/0/en/Pharvaris-Announces-Clinical-Trial-Data-Highlighting-Deucrictibant-for-the-Treatment-of-HAE-to-be-Presented-at-the-2025-US-HAEA-National-Summit.html

    GLOBENEWSWIRE
    27 Jun 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.